Dongkui Xu

441 total citations
25 papers, 328 citations indexed

About

Dongkui Xu is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Dongkui Xu has authored 25 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Dongkui Xu's work include MicroRNA in disease regulation (4 papers), Histone Deacetylase Inhibitors Research (4 papers) and Gastric Cancer Management and Outcomes (3 papers). Dongkui Xu is often cited by papers focused on MicroRNA in disease regulation (4 papers), Histone Deacetylase Inhibitors Research (4 papers) and Gastric Cancer Management and Outcomes (3 papers). Dongkui Xu collaborates with scholars based in China, United States and Hong Kong. Dongkui Xu's co-authors include Haili Qian, Haijuan Wang, Fei Ma, Nan Peng, Qimin Zhan, Chunxiao Li, Changzhi Huang, Jian Liu, Dan Zhao and Hui Li and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Dongkui Xu

24 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dongkui Xu China 11 196 90 88 49 43 25 328
Tao Shen China 9 282 1.4× 60 0.7× 104 1.2× 26 0.5× 27 0.6× 12 388
Bing Yu China 10 231 1.2× 57 0.6× 94 1.1× 30 0.6× 26 0.6× 17 341
Sandipto Sarkar United States 13 242 1.2× 83 0.9× 114 1.3× 33 0.7× 31 0.7× 18 394
Vui King Vincent–Chong Malaysia 15 243 1.2× 124 1.4× 117 1.3× 74 1.5× 32 0.7× 30 484
Jeannette Huaman United States 6 155 0.8× 111 1.2× 73 0.8× 49 1.0× 26 0.6× 7 310
Apple Long United States 6 208 1.1× 98 1.1× 132 1.5× 47 1.0× 19 0.4× 8 375
Chanida Vinayanuwattikun Thailand 13 214 1.1× 116 1.3× 119 1.4× 92 1.9× 10 0.2× 42 381
Xiangde Zhao China 12 310 1.6× 108 1.2× 99 1.1× 19 0.4× 21 0.5× 18 423
Ivana de la Serna United States 9 330 1.7× 129 1.4× 67 0.8× 34 0.7× 60 1.4× 13 447
Xiaoqian He China 13 222 1.1× 87 1.0× 42 0.5× 51 1.0× 18 0.4× 24 309

Countries citing papers authored by Dongkui Xu

Since Specialization
Citations

This map shows the geographic impact of Dongkui Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongkui Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongkui Xu more than expected).

Fields of papers citing papers by Dongkui Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongkui Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongkui Xu. The network helps show where Dongkui Xu may publish in the future.

Co-authorship network of co-authors of Dongkui Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Dongkui Xu. A scholar is included among the top collaborators of Dongkui Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongkui Xu. Dongkui Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Fei, Ting Wang, Dongkui Xu, et al.. (2025). STS2 deficiency revives CD8+T cells from exhaustion and augments checkpoint blockade efficacy in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 13(6). e010735–e010735. 1 indexed citations
2.
Wang, Wenhui, Dongkui Xu, Haiyan Liang, et al.. (2024). PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor‐Initiating Cell Stemness. Advanced Science. 11(48). e2410756–e2410756. 1 indexed citations
3.
Liu, Jian, Chunxiao Li, Xiangyu Chen, et al.. (2023). MTA1 localizes to the mitotic spindle apparatus and interacts with TPR in spindle assembly checkpoint regulation. Biochemical and Biophysical Research Communications. 675. 106–112. 1 indexed citations
4.
Wang, Ting, Chunxiao Li, Nan Peng, et al.. (2023). MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial Metabolism Reprogramming. Advanced Science. 10(25). e2300756–e2300756. 27 indexed citations
5.
6.
Li, Chunxiao, Jinsong Wang, Wenna Wang, et al.. (2022). Expression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity. Military Medical Research. 9(1). 71–71. 13 indexed citations
7.
Peng, Nan, Chunxiao Li, Hongnan Mo, et al.. (2022). Upregulation of MTA1 in Colon Cancer Drives A CD8+ T Cell-Rich But Classical Macrophage-Lacking Immunosuppressive Tumor Microenvironment. Frontiers in Oncology. 12. 825783–825783. 10 indexed citations
8.
Xu, Dongkui, Junlan Qiu, Tao Wen, et al.. (2022). Hormone replacement therapy in relation to the risk of colorectal cancer in women by BMI: a multicentre study with propensity score matching. International Journal of Clinical Oncology. 27(4). 765–773. 4 indexed citations
9.
Liang, Haiyan, Dongkui Xu, Xianhong Tong, et al.. (2022). Biphasic Effect of TNF-α on the Survival and Endocrine Function of Human Ovarian Granulosa Cells. SHILAP Revista de lepidopterología. 49(5). 2 indexed citations
10.
11.
Li, Hui, Jinsong Wang, Zongbi Yi, et al.. (2021). CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. European Journal of Cancer. 145. 92–108. 35 indexed citations
12.
Feng, Qiang, Dongkui Xu, Zhiyuan Wu, et al.. (2021). CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration. Cancer Cell International. 21(1). 169–169. 12 indexed citations
13.
Xu, Dongkui, Zhenguo Zhao, Chao Shang, et al.. (2021). Inhibition of O-glycosylation aggravates GalN/LPS-induced liver injury through activation of ER stress. Immunopharmacology and Immunotoxicology. 43(6). 741–748. 2 indexed citations
14.
Liu, Jian, Chunxiao Li, Jinsong Wang, et al.. (2020). Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. Nature Communications. 11(1). 4455–4455. 31 indexed citations
15.
Liu, Shikai, Lili Song, Hairong Yao, et al.. (2018). Preserved miR-361-3p Expression Is an Independent Prognostic Indicator of Favorable Survival in Cervical Cancer. Disease Markers. 2018. 1–9. 22 indexed citations
16.
Liu, Jian, Haijuan Wang, Fei Ma, et al.. (2014). MTA1 regulates higher‐order chromatin structure and histone H1‐chromatin interaction in‐vivo. Molecular Oncology. 9(1). 218–235. 20 indexed citations
17.
Zhao, Dan, Dongkui Xu, Xuemei Zhang, et al.. (2009). Interaction of Cyclooxygenase-2 Variants and Smoking in Pancreatic Cancer: A Possible Role of Nucleophosmin. Gastroenterology. 136(5). 1659–1668. 50 indexed citations
18.
Liu, Yong-Jun, Yunfeng Li, Haijuan Wang, et al.. (2009). BH3-based Fusion Artificial Peptide Induces Apoptosis and Targets Human Colon Cancer. Molecular Therapy. 17(9). 1509–1516. 15 indexed citations
19.
Xu, Dongkui. (2008). Association between single nucleotide polymorphisms in promoter of COX-2 gene and hereditary susceptibility to hepatocellular carcinoma. Zhonghua gan-dan waike zazhi. 14(12). 840–843. 7 indexed citations
20.
Xu, Dongkui, Ping Zhao, Yongfu Shao, et al.. (2006). [Diagnosis and management of metastatic pancreatic tumors].. PubMed. 28(4). 306–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tao Shen Breakdown of academic impact, for papers by Bing Yu Breakdown of academic impact, for papers by Sandipto Sarkar Breakdown of academic impact, for papers by Vui King Vincent–Chong Breakdown of academic impact, for papers by Jeannette Huaman Breakdown of academic impact, for papers by Apple Long Breakdown of academic impact, for papers by Chanida Vinayanuwattikun Breakdown of academic impact, for papers by Xiangde Zhao Breakdown of academic impact, for papers by Ivana de la Serna Breakdown of academic impact, for papers by Xiaoqian He
Rankless by CCL
2026